Bristol-Myers Squibb Company (ETR:BRM)
Germany · Delayed Price · Currency is EUR 40.18
+0.33 (0.82%)
Jul 16, 2025, 5:35 PM CET
ETR:BRM Revenue
Bristol-Myers Squibb Company had revenue of $11.20B USD in the quarter ending March 31, 2025, a decrease of -5.60%. This brings the company's revenue in the last twelve months to $47.64B, up 4.62% year-over-year. In the year 2024, Bristol-Myers Squibb Company had annual revenue of $48.30B with 7.32% growth.
Revenue (ttm)
$47.64B
Revenue Growth
+4.62%
P/S Ratio
1.85
Revenue / Employee
$1.40M
Employees
34,100
Market Cap
81.37B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 48.30B | 3.29B | 7.32% |
| Dec 31, 2023 | 45.01B | -1.15B | -2.50% |
| Dec 31, 2022 | 46.16B | -226.00M | -0.49% |
| Dec 31, 2021 | 46.39B | 3.87B | 9.09% |
| Dec 31, 2020 | 42.52B | 16.37B | 62.62% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Siemens Healthineers AG | 23.14B |
| Merck KGaA | 21.32B |
| Bayer Aktiengesellschaft | 46.58B |
| Fresenius SE & Co. KGaA | 22.13B |
| Fresenius Medical Care AG | 19.49B |
| Sartorius Aktiengesellschaft | 3.44B |
| Fielmann Group AG | 2.33B |
| Carl Zeiss Meditec AG | 2.17B |
Bristol-Myers Squibb Company News
- 1 day ago - A Closer Look at Bristol-Myers Squibb's Options Market Dynamics - Benzinga
- 2 days ago - Is Bristol-Myers Squibb Still An Undervalued Biopharma Play? - Benzinga
- 7 days ago - Bristol Myers Squibb: Hidden Facts Blur The Strength Of The Company - Seeking Alpha
- 9 days ago - Sign up now: Procurement leaders convene to discuss resilient growth and innovation - Business Insider
- 12 days ago - Price Over Earnings Overview: Bristol-Myers Squibb - Benzinga
- 14 days ago - IDEXX, DexCom lead S&P 500 healthcare gains in Q2; UnitedHealth and Bristol Myers Squibb among top laggards - Seeking Alpha
- 15 days ago - Our bottom 5 stocks for the first half of 2025 and why we still own them - CNBC
- 15 days ago - Bristol-Myers Squibb: Strong Launch Portfolio Amid Market Reset - Seeking Alpha